Acquiring Company
Natera
Acquired Company
Foresight Diagnostics
AustinBoulderBiotechnologyHealth CareGeneticsHealth DiagnosticsBiotechnologyHealth CareDescription
Natera, Inc. has completed a transaction to acquire Foresight Diagnostics in an all-stock deal valued at $275 million, with potential earnouts of $175 million. This acquisition aims to enhance Natera’s capabilities in personalized MRD testing while integrating Foresight's advanced phased variant technology. The deal is set to accelerate the adoption of MRD testing in lymphoma and other solid tumor types.
Who to call at Natera, and when
When Natera changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Natera raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Natera, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Natera. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Natera makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Foresight Diagnostics?
Foresight Diagnostics was acquired by Natera, based in Austin. The deal was reported on December 5, 2025. Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Natera is publicly traded (NTRA) and operates in Biotechnology.
When did Natera acquire Foresight Diagnostics?
Natera's acquisition of Foresight Diagnostics was reported on December 5, 2025. Natera, Inc. has completed a transaction to acquire Foresight Diagnostics in an all-stock deal valued at $275 million, with potential earnouts of $175 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Foresight Diagnostics do?
Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. It is privately held, operating in Biotechnology, and is based in Boulder.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.